Naltrexone Modification of Drinking Effects in a Subacute Treatment and Bar-Lab Paradigm: Influence of OPRM1 and Dopamine Transporter (SLC6A3) Genes
Alcoholism: Clinical and Experimental Research,  Clinical Article

Anton RF et al. – This study does not support a salient role for the opioid receptor (OPRM1) asp40 alone in predicting drinking or naltrexone effects. However, although exploratory and in need of replication, it introduces the possibility that epistasis between the OPRM1 gene and dopamine transporter gene might need to be taken into account when examining differential genetic response to alcohol or medication treatment, especially in early–stage alcoholics.

Methods
  • Two hundred and sixty-five nontreatment-seeking individuals with alcohol dependence were genotyped a priori for the OPRM1 asn40asp SNP and post hoc for DAT (SLC6A3) 9 and 10 VNTRs.
  • Asp40 carriers (n = 43) and matched asn40 homozygotes (n = 40) were randomized to naltrexone or placebo for 7 days before receiving a priming drink and limited-access alcohol consumption in a bar-lab setting.
  • Effects of genotypes on natural drinking as well as drinking, alcohol effects, and response to naltrexone in the bar-lab setting were examined by genotype.

Results
  • There were no significant main effects of naltrexone or OPRM1 genotype, or any medication by OPRM1 interaction, on drinking variables.
  • However, in individuals who had at least one DAT 9 VNTR, and who were also OPRM1 asn40 homozygotes, naltrexone reduced drinks/d consumed under natural conditions (p = 0.006), but not in the bar-lab.
  • OPRM1 asn40 homozygotes (p = 0.028) and DAT 9 VNTR carriers (p = 0.032) had more stimulation to alcohol after the priming drink.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Psychiatry

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Psychiatry Articles

1 Zolpidem and the risk of Parkinson's disease: A nationwide population-based study Journal of Psychiatric Research, August 1, 2014    Clinical Article

2 Vascular Endothelial Growth Factor: A potential diagnostic biomarker for major depression Journal of Psychiatric Research, September 19, 2014    Clinical Article

3 Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials JAMA Psychiatry, October 22, 2014    Evidence Based Medicine    Clinical Article

4 Comparative efficacy and acceptability of drug treatments for bipolar depression: A multiple-treatments meta-analysis Acta Psychiatrica Scandinavica, October 10, 2014    Evidence Based Medicine    Clinical Article

5 Antidepressants and the risk of hyponatraemia: A class-by-class review of the literature Psychosomatics, September 15, 2014    Review Article

6 Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis Schizophrenia Research, September 24, 2014    Clinical Article

7 Comparison of pro-inflammatory cytokines among patients with bipolar disorder and unipolar depression and normal controls Bipolar Disorders, October 3, 2014    Clinical Article

8 Diffusion tensor imaging predictors of treatment outcomes in major depressive disorder The British Journal of Psychiatry, October 8, 2014    Clinical Article

9 A comparison between phone-based psychotherapy with and without text messaging support in between sessions for crisis patients Full Text Journal of Medical Internet Research, October 13, 2014    Free full text    Clinical Article

10 Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression International Journal of Neuropsychopharmacology, October 2, 2014    Clinical Article

11 Association of ARRB1 polymorphisms with the risk of major depressive disorder and with treatment response to mirtazapine Journal of Psychopharmacology, October 16, 2014    Clinical Article

12 Cognitive improvement of attention and inhibition in the late afternoon in children with attention-deficit hyperactivity disorder (ADHD) treated with osmotic-release oral system methylphenidate Journal of Child Neurology, October 15, 2014    Clinical Article

13 Prazosin in the treatment of PTSD Journal of Psychiatric Practice, July 25, 2014    Review Article

14 Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis European Neuropsychopharmacology, September 2, 2014    Evidence Based Medicine    Review Article

15 Attention-deficit/hyperactivity disorder and adverse health outcomes in adults The Journal of Nervous and Mental Disease, October 29, 2014    Clinical Article

16 Therapist-assisted Internet–delivered Cognitive Behavior Therapy for depression and anxiety: Translating evidence into clinical practice Journal of Anxiety Disorders, October 17, 2014    Clinical Article

17 Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia American Journal of Psychiatry, October 6, 2014    Evidence Based Medicine    Clinical Article

18 Internet-delivered exposure-based cognitive-behavioural therapy and behavioural stress management for severe health anxiety: Randomised controlled trial The British Journal of Psychiatry, October 14, 2014    Clinical Article

19 Psychiatric correlates of alcohol and tobacco use disorders in U.S. adults aged 65 years and older: Results from the 2001-2002 National Epidemiologic Survey of Alcohol and Related Conditions The American Journal of Geriatric Psychiatry, October 9, 2014    Clinical Article

20 Cigarette smoking and the onset and persistence of depression among adults in the United States: 1994-2005 Comprehensive Psychiatry, October 28, 2014    Clinical Article

Indexed Journals in Psychiatry : Current Psychiatry, Bipolar Disorders, American Journal of Psychiatry, Addictionmore